SCHEMBL22354597

SCHEMBL22354597

O=C(O)CN1CCN(CC(=O)O)CCN([C@@H](CCN2C(=O)C=CC2=O)C(=O)O)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 1/20 0.42
PTGS1 P23219 4/20 0.39
PTGS2 P35354 4/20 0.39
ALB P02768 1/20 0.38
TACR1 P25103 3/20 0.35
CACNA2D1 P54289 1/20 0.34
CACNA1B Q00975 1/20 0.34
CACNB1 Q02641 1/20 0.34
CACNA1C Q13936 1/20 0.34
FAAH O00519 2/20 0.33
MGLL Q99685 2/20 0.33
HSD17B10 Q99714 1/20 0.33
HSP90AA1 P07900 1/20 0.33
TLR9 Q9NR96 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22779178 1.00 SLC6A9 (0.42) SLC6A9PTGS1PTGS2ALBTACR1
SCHEMBL19016167 0.94 SLC6A9 (0.38) SLC6A9PTGS1PTGS2ALBTACR1
SCHEMBL23014569 0.84 ALB (0.52) SLC6A9PTGS1PTGS2ALBALDH1A1
SCHEMBL24728937 0.84 ALB (0.52) SLC6A9PTGS1PTGS2ALBALDH1A1
SCHEMBL15362876 0.84 ALB (0.51) SLC6A9PTGS1PTGS2ALBALDH1A1
SCHEMBL23762982 0.84 ALB (0.51) SLC6A9PTGS1PTGS2ALBALDH1A1
SCHEMBL9094862 0.82 ALB (0.54) ALB
SCHEMBL16922674 0.81 SLC6A9 (0.43) SLC6A9ALBTACR1CACNA2D1CACNA1B
SCHEMBL15362897 0.79 ALB (0.47) SLC6A9PTGS1PTGS2ALBALDH1A1
SCHEMBL19016237 0.77 ALB (0.35) SLC6A9ALBTACR1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127047-A1 SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES ANTAROS MEDICAL AB (SE) 2023-04-27 US disclosed
US-20230127047-A1 SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES ANTAROS MEDICAL AB (SE) 2023-04-27 US disclosed
WO-2021198229-A1 SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES ANTAROS MEDICAL AB (SE) 2021-10-07 WO disclosed
US-11046743-B2 Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes ANTAROS MEDICAL AB (SE) 2021-06-29 US disclosed
US-20200262885-A1 SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES ANTAROS MEDICAL AB (SE) 2020-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127047-A1 SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES GIPR, GRPR, GLP1R SLC6A9 934/4885PTGS1 3456/4885PTGS2 3855/4885
US-20200262885-A1 SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES GLP1R, GCGR, GIPR SLC6A9 914/4885PTGS1 3836/4885PTGS2 3986/4885
US-11046743-B2 Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes GLP1R, GCGR, GIPR SLC6A9 914/4885PTGS1 3836/4885PTGS2 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.